Department of Psychology, Chestnut Hill College, 9601 Germantown Ave, Philadelphia, PA 19118.
Department of Psychology, Chestnut Hill College, Philadelphia, Pennsylvania, USA.
J Clin Psychiatry. 2018 Sep 11;79(5):17m11807. doi: 10.4088/JCP.17m11807.
Given the chronic, episodic nature of panic disorder, it is important to examine long-term outcomes of patients who respond well to various psychotherapies.
Out of 116 patients with DSM-IV panic disorder who evidenced a ≥ 40% reduction in panic and avoidance symptoms on the Panic Disorder Severity Scale (PDSS) after 12-14 weeks of panic-focused psychodynamic psychotherapy, cognitive-behavioral therapy, or applied relaxation training as part of a 2-site randomized controlled trial conducted between January 2007 and July 2012, 91 patients provided at least 1 PDSS datapoint during follow-up. Patients were assessed at each of the 12 following months using the PDSS, the Sheehan Disability Scale (SDS), and the Hamilton Depression Rating Scale (HDRS) and twice during the follow-up period with the Anxiety Disorders Interview Schedule.
Patients with panic disorder who responded to 1 of 3 treatments maintained their gains on the PDSS, SDS, and HDRS with no differences by condition in rates of change over the follow-up period (all P values ≥ .20). Similarly, 57% of improved patients did not have a panic disorder diagnosis by the end of 1 year, regardless of the treatment received. No differences in rates of panic disorder diagnosis were found across treatment conditions at either 6 months or 12 months (all P values ≥ .78). Results should be interpreted in light of the fact that patients giving data at follow-up experienced lower symptom levels at treatment termination than those not providing data.
Improvement in any of the 3 treatments examined in this trial was largely maintained for a year following the end of therapy. Future treatment development could focus on factors to increase the level of response in the active phase of therapy.
ClinicalTrials.gov identifier: NCT00353470.
鉴于惊恐障碍具有慢性、间歇性的特点,因此,对接受各种心理治疗后症状明显缓解的患者进行长期疗效随访是非常重要的。
在 2007 年 1 月至 2012 年 7 月期间开展的一项为期 2 个地点的随机对照试验中,116 例 DSM-IV 惊恐障碍患者在接受 12-14 周的惊恐聚焦心理动力学心理治疗、认知行为治疗或应用放松训练后,惊恐和回避症状的惊恐障碍严重程度量表(PDSS)评分至少降低了 40%,其中 91 例患者在随访期间至少提供了 1 次 PDSS 数据点。在接下来的 12 个月中,患者每 1 个月使用 PDSS、Sheehan 残疾量表(SDS)和汉密尔顿抑郁评定量表(HDRS)进行评估,并在随访期间两次使用焦虑障碍访谈表进行评估。
对 3 种治疗方法中的 1 种有反应的惊恐障碍患者在 PDSS、SDS 和 HDRS 上保持了疗效,在随访期间的变化率没有因治疗条件的不同而不同(所有 P 值均≥.20)。同样,无论接受何种治疗,1 年后有 57%的改善患者未被诊断为惊恐障碍。在 6 个月或 12 个月时,不同治疗条件下的惊恐障碍诊断率没有差异(所有 P 值均≥.78)。在随访中提供数据的患者在治疗结束时的症状水平低于未提供数据的患者,因此,结果应结合这一事实进行解读。
在本试验中,接受任何 3 种治疗之一的患者在治疗结束后 1 年内疗效大多得以维持。未来的治疗发展可以侧重于提高治疗活跃期反应水平的因素。
ClinicalTrials.gov 标识符:NCT00353470。